TY - JOUR
T1 - 68Ga-PSMA-PET
T2 - added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer
AU - Malaspina, Simona
AU - De Giorgi, Ugo
AU - Kemppainen, Jukka
AU - Del Sole, Angelo
AU - Paganelli, Giovanni
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Positron emission tomography (PET) has been commonly and successfully used, in combination with computed tomography (CT) and more recently magnetic resonance (MRI), in the workup of intermediate or high-risk prostate cancer (PCa). Nowadays, new specific receptor targeted PET tracers in prostate cancer imaging have been introduced; one of the most used is 68Ga-PSMA, that evaluates the expression of prostate-specific membrane antigen (PSMA). This tracer has been rapidly taken into account for its better sensitivity and specificity compared to lipid metabolism tracers, such as 11C/18F labelled fluorocholine. Besides, in the era of theranostics, this tracer is having a useful application not only for imaging but also for therapeutic purposes. The aim of this review article is, in the first part, to give an overview of the main indications and future development of 68Ga-PSMA imaging, using PET/CT or PET/MRI, according to the clinical course of the disease and in view of the current use of multiparametric MRI (mpMRI) and choline PET in the management of PCa. In the second part, a brief overview of the promising 18F-labelled PSMA tracers and the current use of PSMA radionuclide therapy will be provided.
AB - Positron emission tomography (PET) has been commonly and successfully used, in combination with computed tomography (CT) and more recently magnetic resonance (MRI), in the workup of intermediate or high-risk prostate cancer (PCa). Nowadays, new specific receptor targeted PET tracers in prostate cancer imaging have been introduced; one of the most used is 68Ga-PSMA, that evaluates the expression of prostate-specific membrane antigen (PSMA). This tracer has been rapidly taken into account for its better sensitivity and specificity compared to lipid metabolism tracers, such as 11C/18F labelled fluorocholine. Besides, in the era of theranostics, this tracer is having a useful application not only for imaging but also for therapeutic purposes. The aim of this review article is, in the first part, to give an overview of the main indications and future development of 68Ga-PSMA imaging, using PET/CT or PET/MRI, according to the clinical course of the disease and in view of the current use of multiparametric MRI (mpMRI) and choline PET in the management of PCa. In the second part, a brief overview of the promising 18F-labelled PSMA tracers and the current use of PSMA radionuclide therapy will be provided.
KW - Magnetic resonance imaging
KW - Positron emission tomography
KW - Prostate-specific membrane antigen
KW - Prostte cancer
UR - http://www.scopus.com/inward/record.url?scp=85052561468&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052561468&partnerID=8YFLogxK
U2 - 10.1007/s11547-018-0929-9
DO - 10.1007/s11547-018-0929-9
M3 - Review article
C2 - 30116970
AN - SCOPUS:85052561468
SN - 0033-8362
VL - 123
SP - 952
EP - 965
JO - Radiologia Medica
JF - Radiologia Medica
IS - 12
ER -